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The association of interleukin-2 (IL-2), interferon alpha-2a (IFNa), 5-fluorouracil (5-FU) has been reported to induce response in
metastatic renal cell carcinoma (MRCC). This study evaluated IL-2, IFNa and 5FU as second-line treatment after failure under
immunotherapy. A total of 35 patients received IL-2, at 9 10
6IUm
 2, once or t.i.d, 5 days a week, every other week. Interferon
alpha was administered at 6MUI, TIW along with IL-2 every week. 5-Fluorouracil was given at 750mgm
 2day
 1 on days 1–5 every
4 weeks. One cycle lasted 8 weeks. All patients were evaluable for response and toxicity. There were two objective responses (5.7%)
and 14 stable diseases (40%). Survival was 14 months. In all, 17 patients experienced grade 3 toxicity. The predictive factor for
progression to second-line immunotherapy was the results of first-line immunotherapy, and performance status, delay from primary
tumour to metastases and response or stabilisation to chemo-immunotherapy for survival. IL-2, IFNa and 5-FU induce low objective
response but stabilisation in patients with MRCC having failed with immunotherapy, and may be considered only in selected patients
on performance status, stabilisation or response after first-line immunotherapy and interval from their primary tumour to metastases.
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The prognosis of patients with metastatic renal cell carcinoma
(MRCC) remains poor with an estimated 5-year survival of 0–20%
(Linehan et al, 2001). Interferon alpha (IFNa) and interleukin-2
(IL-2) have shown objective responses in 10–25% of patients
(Rosenberg et al, 1989; Atzpodien et al, 1993; Buter et al, 1993; Fyfe
et al, 1995; Savage and Muss, 1995; Yang and Rosenberg, 1997;
Ne ´grier et al, 1998) and long-lasting responders (Fyfe et al, 1996).
More recently, INFa has been shown to prolong survival compared
to hormonotherapy (Medical Research Council Renal Cancer
Collaborators, 1999), although progression occurred in most
patients.
When this study was designed, no effective second-line
treatment arrising from chemotherapy (Yagoda et al, 1995) or
cellular therapy (Figlin et al, 1998) was available. Only one study in
13 patients with MRCC treated with s.c. IL-2 after failure under
IFNa reported four partial responses (Lissoni et al, 1992).
Based on preclinical data suggesting a synergism between IL-2
and 5-fluorouracil (5-FU) on one hand and IFNa and 5-FU on the
other, added to the well-known synergism of the association of IL-
2 and IFNa (Cameron et al, 1988), the combination of IL-2, IFNa
and 5-FU has been investigated in renal cell carcinoma. In animal
experiments, IL-2 potentiates the antitumoral activity of various
cytotoxic drugs including 5-FU (Gauny et al, 1989; Kawano et al,
1994; Lee et al, 1994). Modulation of 5-FU with IFNa has been
more extensively studied. IFNa induces thymidine phosphorylase,
enhancing the conversion of 5-FU to the active 5-fluorodeoxyur-
idine monophosphate (FdUMP) inducing the depletion of
thymidine triphosphate pools and DNA breakpoint, leading so
far to an increase of the cytoxicity of 5-FU (Wadler et al, 1990;
Morita and Tokue, 1999). Moreover, IFNa inhibits the intracellular
uptake of thymidine (Pfeffer and Tamm, 1984), and thymidilate
synthase (Elias and Sandoval, 1989). At the beginning of the 1990s,
clinical trials reported an increased response rate when 5-FU was
added to IL-2 and IFNa (Atzpodien et al, 1993; Hofmockel et al,
1996; Joffe et al, 1996; Ellerhorst et al, 1997). Groups using an
identical schedule as Atzpodien et al showed the response rate as
ranging from 16 to 48% (Atzpodien et al, 1993; Hofmockel et al,
1996; Joffe et al, 1996; Ellerhorst et al, 1997).
Owing to the lack of a validated second-line treatment after
immunotherapy in MRCC, the possibility that a second-line
chemo-immunotherapy might prevent progression under previous
immunotherapy was tested. Based on the reported higher response
rate when 5-FU was added to IL-2 and IFNa, this study was
designed to test the ability of the association of IL-2, IFNa and 5-
FU to induce an objective response or at least stabilization while
patients had progressed under IFNa and/or IL-2.
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Patients
Eligible patients had histologically proven renal cell carcinoma
with progressive metastatic disease after a previous immunother-
apy with IFNa and/or IL-2. Patients were adults less than 75 years
of age, who had a Karnofsky performance status 470%. Patients
were required to have measurable metastatic disease. They were
not to have received either immunotherapy or radiotherapy in the
previous 4 weeks. Adequate organ functions were required without
cardiac, respiratory, hepatic, renal, neurologic or psychiatric
disorders. They had normal blood cell counts, normal bilirubin
level, creatinine concentrations less than 180mmol/l
 1, normal
cardiac function and a life expectancy of at least 3 months. Patients
with severe infection, known positivity of human immunodefi-
ciency virus test or chronic hepatitis were excluded, as were
patients on corticosteroids. Patients did not have history of an
organ allograft or other malignancies. Pregnant or lactating women
were also excluded.
The trial was approved by the CCPPRB in Bordeaux according to
the French law. The study was conducted according to the
principles of Good Clinical Practice.
Pretreatment evaluation
In addition, clinical history and physical examination were
recorded for all patients. Preinclusion staging included cerebral,
thoracic, abdominal CT scans and a bone scan. Written informed
consent was obtained before inclusion in the trial.
Treatment plan (Table 1)
Interleukin-2 (Proleukin; Chiron Therapeutics, Suresnes, France)
was given subcutaneously at a dose of 9 10
6IUm
 2, twice on
days 1 and 2, once a day on days 3–5 and every other week for 8
weeks. Interferon alpha (Introna; Schering Plough, Levallois-
Perret, France) was administered at a dose of 6 10
6IU, three
times a week, during weeks with IL-2. 5-Fluorouracil was delivered
by a continuous infusion at 750mgm
 2day
 1 for five consecutive
days every 4 weeks, starting with IL-2 and IFNa in the first week.
Each time an objective response or a stable disease occurred, an
additional identical course of treatment was given after 1 week’s
rest.
Evaluation of treatment
Evaluation of tumour response, including thoracic and abdominal
CT-scan and a bone scan, was performed every 8 weeks of
treatment. The World Health Organization (WHO) criteria were
used to determine tumour response (Miller et al, 1981). Complete
response (CR) was defined as the complete disappearance of all
measurable and evaluable tumour sites for at least 4 weeks. The
duration of CR was calculated from the first date of documentation
of CR to the date of the first evaluation of disease progression.
Partial response (PR) was considered to be a X50% decrease in
the sum of products of the greatest perpendicular diameters lasting
for at least 4 weeks, with no increase in known lesions and without
appearance of any new lesions. When the evaluation showed a
o50% decrease in lesions or a o25% increase, patients were
considered to have a stable disease (SD). The duration of PR and
SD was calculated from the first day of treatment. Progressive
disease (PD) was considered to be when any lesion increased by
X25% or when a new lesion appeared. The results of the
successive bone scans were considered as PD in the case of
appearance of new spots, stable if not, and complete regression
only if all spots disappeared. Patients who presented with a CR, PR
or SD were evaluated every 2–3 months during the first year and
then every 4–6 months.
Survival duration was evaluated from the start of treatment to
the date of the last contact or the date of death. Progression-free
survival was calculated from the start of treatment to the date of
last follow-up or the date of progression.
Toxicities encountered were classified according to the WHO
grading system.
Statistical analysis
The primary end point was the response rate. The secondary end
points were stabilisation rate, prolonged stabilisation rate (at least
a period following chemo-immunotherapy as long as two cycles of
treatment: 2 [2 8 weeks]¼32 weeks or 8 months), overall
survival, toxicity and prognostic factors for progression under
second-line chemo-immunotherapy and overall survival.
The trial was conducted according to the two-stage Gehan
design (Gehan, 1961). As first-line treatment, IFNa and IL-2 have
shown objective responses in 18% of patients included into trials
that we conducted (Ne ´grier et al, 1998; Ravaud et al, 1994); we
planned to detect a response rate X10%. We assessed the response
rate after 29 patients had been recruited to have a 95% chance of
detecting at least one response when the actual response rate was
X10%. If at least one response occurred in the first 29 patients, we
planned to increase the number of patients to assess the response
rate with 5% precision (i.e., one response justified the inclusion of
four more patients: at least 33 patients for the study).
To study prognostic factors, patients presenting response and
stabilisation were pooled. Progressive disease was considered in
the case of progression of the disease at tumour evaluation
performed at 8 weeks. The following potential clinical prognostic
parameters were analysed: gender, time from primary tumor to
occurrence of metastases (o12 months vs X12 months), type of
first-line immunotherapy (IL-2 vs IFNa alone), response to first-
line immunotherapy (PD vs objective response or stabilisation),
number of sites before second-line treatment (1 vs 41) and
general status (Karnofsky X90% vs o90%). The association
between response and stabilisation after second-line immunother-
apy was assessed using the w
2 test and survival distribution was
estimated using the Kaplan–Meier method (Kaplan and Meier,
1958). The relationship between survival and parameters was
analysed with the log-rank test (Mantel, 1966). Parameters that
were significantly associated with survival at a P-value of o0.10
were included in a forward stepwise Cox model (Mantel, 1966).
RESULTS
Patient characteristics
From September 1994 to April 2000, 35 patients with MRCC were
entered into the trial. All patients were evaluable for response and
for toxicity and their main characteristics are outlined in Table 2.
Most patients had an ambulatory performance status: 21 patients
(60%) had a Karnofsky performance status X90%, while 14 (40%)
patients had a Karnofsky performance status o90%. The time
from diagnosis of renal cell carcinoma to the occurrence of
metastases was less than 12 months in 25 patients (71.4%). All
Table 1 Schedule and dose of treatment
IL-2 * * }}}** }}}
IFNa ## # ## #
5-FU fff f f
d a y1 2 3451 5 1 7 1 9 2 9
Second cycle
*¼IL-2: 9 10
6IUm
 2 2, }¼IL-2: 9 10
6IUm
 2,#¼IFNa:6 10
6IU, f¼5-
FU 750mgm
 2.
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diagnosis of metastatic disease to first immunotherapy was 3.4
months (range: 0–29 months). For the first-line immunotherapy,
21 patients were treated with IFNa, nine with IL-2 and five with the
association of IFNa and IL-2. Six patients (17.2%) showed an
objective response (1 CR and 5 PR), while 18 (51.4%) had a SD. In
a median time of 9 months (range: 2–77 months), patients were
included in this study. At the time of second-line treatment, the
metastatic disease was localised in the lung (27 patients),
mediastinal or abdominal lymph nodes (17 patients), bone (six
patients), liver (four patients) and at the nephrectomy site (three
patients). In all, 26 patients (74%) had at least two tumour sites at
the time of second-line treatment initiation.
Administration of treatment and toxicity
During cycles, the median dose given to patients was 100% for
each drug. The main toxicities (Table 3) were decrease in
performance status (28 patients, 80%), fever (24 patients, 69%),
nausea/vomiting (17 patients, 49%), diarrhoea (12 patients, 34%),
cutaneous erythema (11 patients, 31%), hypotension (eight
patients, 23%) and haematological disturbances (11 patients,
31%). In all, 17 patients (49%) had treatment-related grade 3
toxicity; 27 grade 3 events were reported: fever (six patients, 17%),
nausea/vomiting (four patients, 11%), decrease in performance
status, hypotension (three patients, 9%), diarrhoea, cardiotoxicity,
mucositis (two patients) and skin erythema, anaemia, neutropenia
and hypothyroidism (one patient). Nevertheless, none had grade 4
toxicity or died within the treatment course.
Response to treatment and survival
The median follow-up was 14 months. At the evaluation performed
after 8 weeks of treatment, two patients (5.7%; 95% CI: 0.07–
19.15%) had achieved an objective response, with one CR obtained
after an immediate subsequent mediastinal radiotherapy. The
duration of response was 6 and 56þ months. In all, 14 patients
(40%; 95% CI: 23.8–57.9%) had SD for a median time of 4 months
(range: 2–16 months), including four patients (11.4%) with SD
48 months, while 19 showed disease progression. The sites of
response were lung and lymph nodes for both patients. The
median survival of all patients was 14 months (95% CI: 10.4–17.7
months) (Figure 1). Patients who showed stabilisation or an
objective response had a median survival of 22 months (95% CI:
10.2–33.8 months), while those with a PD had a median survival of
9 months (95% CI: 4.7–13.3 months).
Table 2 Characteristics of patients
Characteristics No. %
Eligible patients 35
Patients assessable
for toxicity 35 100
for response 35 100
Men/women 27/8 77/23
Age (years) median (range) 62 (25–75)
Performance status (Karnofsky)
100% 7 20
90% 14 40
80% 12 34.3
70% 2 5.7
Time from diagnosis to first metastases
o12 months 25 71.4
X12 months 10 28.6
Prior nephrectomy 35 100
Prior immunotherapy
IFN 21 60
IL-2 9 25.7
IL-2+IFN 5 14.3
Response to first-line immunotherapy
IFN (CR, PR, SD, PD) 1, 2, 12, 6
IL-2 (CR, PR, SD, PD) 0, 1, 4, 4
IL-2+IFN (CR, PR, SD, PD) 0, 2, 2, 1
Site of metastatic disease
Lung 27 77.1
Mediastinal lymph nodes 14 40
Bone 6 17
Abdominal lymph nodes 5 14
Liver 4 11
Recurrence at nephrectomy site 3 9
Others 8 23
Number of sites with metastases
1 9 25.7
41 26 74.3
IFN¼interferon, IL-2¼interleukin-2, CR¼complete response, PR¼partial re-
sponse, SD¼stable disease, PD¼progressive disease.
Table 3 Toxicity
Number of patients (%)
with toxicities by WHO
grades I, II, III and IV
I (%) II (%) III %) IV (%)
Decrease in performance status 8 (23) 17 (49) 3 (9) 0
Fever 1 (3) 17 (49) 6 (17) 0
Diarrhoea 2 (6) 8 (23) 2 (6) 0
Nausea/vomiting 5 (14) 8 (23) 4 (11) 0
Local skin pain 0 2 (6) 0 0
General skin disorders 5 (14) 5 (14) 1 (3) 0
Hypotension 1 (3) 4 (11) 3 (9) 0
Mucositis 3 (9) 0 2 (6) 0
Cardiotoxicity 0 0 2 (6) 0
Neurological 0 1 (3) 0 0
Psychiatric 0 3 (9) 0 0
Infection 0 2 (6) 0 0
Weight gain 1 (3) 0 0 0
Haematological 5 (14) 4 (11) 2 (6) 0
Increase in transaminases 2 (6) 0 0 0
Hypercreatininaemia 2 (6) 0 0 0
Others 0 4 (11) 1 (3) 0
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Figure 1 Overall survival.
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lPredictive factors for progression to second-line
immunotherapy
In univariate analysis, only the results of primary immunotherapy:
stabilisation or objective response vs progression were signifi-
cantly predictive for PD under second-line immunotherapy
treatment (w
2, P: 0.026). Neither gender, time from primary
tumour to occurrence of metastases (o12 months vs X12
months), type of first-line immunotherapy (IL-2-based treatment
vs IFNa alone), number of sites before second-line treatment (1 vs
41) nor general status (Karnofsky X90 vs o90%) reached
statistical significance.
Predictive factors for survival following second-line
immunotherapy
In univariate analysis, factors significantly (Po0.05) associated
with better survival were objective response or stabilisation after
second-line treatment (Po0.001) and general status at the time of
second-line treatment (Po0.01). Neither the type of first-line
immunotherapy nor the number of sites at second-line treatment
was predictive of outcome.
Parameters showing an association with survival in univariate
analysis with a degree of significance o0.10 were included in a
forward stepwise Cox mutivariate analysis. General performance
status (Karnofsky X90% vs o90%) (P: 0.003), time from primary
tumour to metastases (P: 0.033) and response or stabilisation to
second-line treatment (P: 0.038) were considered as independent
factors predictive of survival (Table 4).
DISCUSSION
The RR obtained in this study after a second-line immunotherapy-
based treatment remains low (two out of 35 patients) despite one
prolonged complete remission (456 months). Since the start of
the study, only two other studies have examined this theme
(Paolorossi et al, 1995; Escudier et al, 1999). A large study in 113
patients confirmed the low response (four patients, 3.5%) and
stabilisation (13 patients, 11.5%) rates, following a switch from
IFNa to IL-2 and from IL-2 to IFNa after failure of the first-line
cytokine therapy (Escudier et al, 1999). In the former study
(Escudier et al, 1999), none of the patients received the association
of both cytokines after one had already failed. In another study
(Paolorossi et al, 1995) following the initial work of Lissoni et al
(1992), 15 patients received IFNa and vinblastine after failure
under IL-2. Two patients showed an objective response and five
had stabilisation (Paolorossi et al, 1995).
Nevertheless, the occurrence of stabilisation in these circum-
stances, second-line treatment in patients, especially while they are
still in a good general performance status (Karnofsky X90%) and
when no alternative second-line treatment for renal cell carcinoma
is available other than inclusion in clinical trials, could be
considered to be of clinical interest. Furthermore, in this study,
those patients with stabilisation or an objective response had a
prolonged median survival of 22 months even after a second-line
treatment. Nevertheless, spontaneous slow progression and/or
long stabilisation of renal cell carcinoma without any antitumoral
treatment may affect interpretation of survival outside compared
phase III clinical trials. For this reason, it was considered useful
when making decisions to point out predictive factors for outcome
following a second-line immunotherapy-based treatment. This
study shows that the most clinical significant predictive factor for
no progressive disease at 8 weeks under second-line chemo-
immunotherapy is the efficacy of first-line immunotherapy, which
has not been assessed until now. Only one study reported that only
patients with SD or transient responders with first-line cytokine
treatment were responders (three out of four responders among
113 treated patients) (Escudier et al, 1999). In our study,
parameters favourably affecting survival were a good general
performance status at initiation of second-line treatment (Kar-
nofsky X90%), the delay from primary tumour to metastases
(412 months) and the response to second-line treatment.
Previous studies on prognostic factors for survival in MRCC,
especially those carried out in patients under immunotherapy,
showed both general performance status and delay from primary
tumour to metastases to affect survival significantly (Palmer et al,
1992; Ne ´grier et al, 2002). As the efficacy of second-line
immunotherapy-based treatment was significantly correlated to
the efficacy of the first-line treatment and as the second-line
treatment had a significant impact on survival, it would have been
helpful to study the correlation of survival to the first-line
treatment, but the study was not designed for this purpose.
While a second-line immunotherapy-based treatment may be
considered in selected patients, this study does not provide
sufficient evidence that the association of IL-2, IFNa and 5-FU and
the schedule used are a standard. This protocol is closely related to
the schedule designed for other clinical research trials with IL-2,
IFNa and 75-FU within the framework of the French Immu-
notherapy Group (Ravaud et al, 1998; Ne ´grier et al, 2000). These
large studies showed an unexpectedly low response rate (Ravaud
et al, 1998; Ne ´grier et al, 2000) like the present study, compared to
more promising results obtained by others (Atzpodien et al, 1993;
Hofmockel et al, 1996; Joffe et al, 1996; Ellerhorst et al, 1997;
Tourani et al, 1998; Allen et al, 2000; Dutcher et al, 2000; Elias et al,
2000; van Herpen et al, 2000).
Toxicities encountered by patients during this study were
moderate as expected with no grade 4 WHO toxicity and 49% of
grade 3. Although the study was performed with second-line
treatment, the toxicity profile did not show any differences
compared to trials performed with first-line treatment (Ravaud
et al, 1998; Ne ´grier et al, 2000).
In conclusion, we achieved 5.7% of objective response and 40%
of stabilisation including 11.4% prolonged stabilisation 48
months with IL-2, IFNa, 5-FU in patients with renal cell carcinoma
in whom previous first-line immunotherapy failed. Therefore, the
clinical benefit has to be considered as limited. Nevertheless,
second-line immunotherapy may be considered only for selected
patients who show either stabilisation or an objective response at
evaluation of first-line immunotherapy, who have a good general
status and a delay from the primary tumour to metastasis longer
than 12 months. The recommended protocol therefore requires
further evaluation.
Table 4 Univariate and multivariate stepwise Cox model analysis of survival for all patients
Univariate
Multivariate
Prognostic factor P HR 95% CI P
Objective response and stabilisation to second–line immunotherapy with IL-2, IFNa and 5-FU 0.006 2.43 1.05–5.6 0.038
General performance status (Karnofsky X90 vs o90%) 0.007 3.72 1.55–8.91 0.003
Time interval from primary tumour to occurrence of metastases (p12 vs 412 months) 0.07 2.71 1.08–6.78 0.033
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